| |
Male (n=704 )
|
Female (n=769)
|
|---|
|
Willingness toward drug susceptibility genetic studies
| | | |
Willingness toward drug susceptibility genetic studies
| | | |
|---|
|
Yes (n=339)
|
Neutral or No (n=348)
|
ORa
|
95 % CI
|
P-value
|
Yes (n=360)
|
Neutral or No (n=391)
|
ORa
|
95 % CI
|
P-value
|
|---|
|
n (%)
|
n (%)
| | | |
n (%)
|
n (%)
| | | |
|---|
|
High awareness of the Nagahama study
|
131 (38.9)
|
77 (22.5)
|
2.06
|
1.40–3.03
|
<0.001
|
200 (56.0)
|
178 (46.4)
|
1.28
|
0.92–1.79
|
0.150
|
|
Self-rated understanding of terminology
|
|
High
|
162 (47.9)
|
88 (25.3)
|
1
| | |
117 (32.8)
|
67 (17.5)
|
1
| | |
|
Middle
|
120 (35.5)
|
124 (35.6)
|
0.58
|
0.39–0.87
|
0.008
|
148 (41.5)
|
119 (31.2)
|
0.81
|
0.53–1.22
|
0.307
|
|
Low
|
56 (16.6)
|
136 (39.1)
|
0.33
|
0.20–0.54
|
<0.001
|
92 (25.8)
|
196 (51.3)
|
0.35
|
0.22–0.55
|
<0.001
|
|
The use of genetic information is helpful for disease treatment
|
311 (94.0)
|
241 (71.9)
|
3.41
|
1.93–6.01
|
<0.001
|
317 (90.1)
|
272 (76.0)
|
2.51
|
1.54–4.07
|
<0.001
|
|
Concerns
|
|
Financial infusion
|
268 (82.5)
|
247 (74.6)
|
0.98
|
0.60–1.60
|
0.941
|
280 (80.2)
|
260 (73.2)
|
0.90
|
0.59–1.38
|
0.629
|
|
Privacy concerns
|
199 (60.9)
|
197 (59.3)
|
0.93
|
0.59–1.45
|
0.739
|
200 (56.7)
|
190 (52.9)
|
0.94
|
0.63–1.40
|
0.762
|
|
Discriminations
|
139 (42.0)
|
147 (44.3)
|
0.83
|
0.53–1.28
|
0.289
|
145 (41.2)
|
127 (35.7)
|
1.17
|
0.78–1.75
|
0.459
|
|
Unexpected negative effects
|
131 (39.7)
|
133 (39.9)
|
1.09
|
0.70–1.70
|
0.696
|
117(33.1)
|
112 (31.1)
|
0.97
|
0.63–1.49
|
0.891
|
|
Cloned human beings
|
114 (34.5)
|
122 (36.9)
|
0.85
|
0.54–1.34
|
0.934
|
143 (40.7)
|
137 (38.3)
|
1.04
|
0.67–1.61
|
0.872
|
|
Belief
|
|
Company or government
|
161 (49.4)
|
137 (41.4)
|
1.32
|
0.89–1.94
|
0.167
|
143 (40.7)
|
137 (38.3)
|
0.89
|
0.61–1.29
|
0.529
|
- aAdjusted according to age and formal education duration
